Nanobiotix is a nanomedicine company committed to changing the face of cancer treatment by bringing nanophysics to the heart of the cell. Our lead product NBTXR3 received first European market approval in 2019 and is being developed across 15 clinical trials with a primary focus on global registration for the treatment of head and neck cancers.